Specifically, CD146+ CAFs can lead to persistent estrogen-dependent proliferation and breast cancer cells sensitivity to tamoxifen, while CD146− CAFs can suppress estrogen receptor expression and response of cancer cells to estrogen, thereby resulting in tamoxifen resistance (25). This evidence concerns the gene MCAM and breast carcinoma.